{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:39:08Z","timestamp":1761183548852,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.dmpk.2020.06.008","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T04:15:58Z","timestamp":1594786558000},"page":"485-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Applications of a grid-based CYP3A4 Template system to understand the interacting mechanisms of large-size ligands; part 4 of CYP3A4 Template study"],"prefix":"10.1016","volume":"35","author":[{"given":"Takahiro","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Yamazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tohkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dmpk.2020.06.008_bib1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/03602532.2011.624103","article-title":"Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order","volume":"43","author":"Yamazoe","year":"2011","journal-title":"Drug Metab Rev"},{"issue":"4","key":"10.1016\/j.dmpk.2020.06.008_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2133\/dmpk.DMPK-11-RG-004","article-title":"Predicting oxidation sites with order of occurrence among multiple sites for CYP4A-mediated reactions","volume":"26","author":"Yamaura","year":"2011","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmpk.2020.06.008_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2133\/dmpk.DMPK-10-RG-097","article-title":"Development of two-dimensional template system for the prediction of CYP2B6-mediated reaction sites","volume":"26","author":"Koyama","year":"2011","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmpk.2020.06.008_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/dmd.111.043125","article-title":"Unimolecular and bimolecular binding system for the prediction of CYP2D6-mediated metabolism","volume":"40","author":"Sato","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmpk.2020.06.008_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.dmpk.2016.07.005","article-title":"Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 1. Focusing on polycyclic arenes and the related chemicals","volume":"31","author":"Yamazoe","year":"2016","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2020.06.008_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.dmpk.2017.05.004","article-title":"Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 2: solving substrate interactions of CYP1A2 with non-PAH substrates on the template system","volume":"32","author":"Yamazoe","year":"2017","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmpk.2020.06.008_bib7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.dmpk.2019.02.001","article-title":"Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions Part 3: difference in substrate specificity of human and rodent CYP1A2 and the refinement of predicting system","volume":"34","author":"Yamazoe","year":"2019","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmpk.2020.06.008_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.dmpk.2018.10.001","article-title":"Reconstitution of CYP3A4 active site through assembly of ligand interactions as a grid-template: solving the modes of the metabolism and inhibition","volume":"34","author":"Yamazoe","year":"2019","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmpk.2020.06.008_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.dmpk.2019.05.003","article-title":"Solving the interactions of steroidal ligands with CYP3A4 using a grid-base template system","volume":"34","author":"Goto","year":"2019","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmpk.2020.06.008_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.dmpk.2019.10.008","article-title":"Prediction of regioselectivity and preferred order of CYP1A1-mediated metabolism: solving the interaction of human and rat CYP1A1 forms with ligands on the template system","volume":"35","author":"Yamazoe","year":"2020","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmpk.2020.06.008_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.dmpk.2020.01.001","article-title":"Versatile applicability of a grid-based CYP3A4 Template to understand the interacting mechanisms with the small-size ligands; part 3 of CYP3A4 Template study","volume":"35","author":"Yamazoe","year":"2020","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2020.06.008_bib12","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.bmc.2005.10.015","article-title":"In\u00a0vitro oxidative metabolism study of (-)-rhazinilam","volume":"14","author":"Decor","year":"2006","journal-title":"Bioorg Med Chem"},{"issue":"7","key":"10.1016\/j.dmpk.2020.06.008_bib13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acs.chemrestox.8b00005","article-title":"Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib","volume":"31","author":"Amaya","year":"2018","journal-title":"Chem Res Toxicol"},{"issue":"7","key":"10.1016\/j.dmpk.2020.06.008_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0090-9556(24)15349-4","article-title":"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies","volume":"28","author":"Desta","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2020.06.008_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bcp.2012.04.001","article-title":"Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites","volume":"84","author":"Ghassabian","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.dmpk.2020.06.008_bib16","first-page":"2012","article-title":"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans","volume":"6","author":"Santos","year":"2000","journal-title":"Clin Canc Res"},{"issue":"3","key":"10.1016\/j.dmpk.2020.06.008_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/dmd.31.3.275","article-title":"Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation","volume":"31","author":"Treluyer","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmpk.2020.06.008_bib18","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1124\/dmd.113.052191","article-title":"Intestinal first-pass metabolism by cytochrome P450 and not p-glycoprotein is the major barrier to amprenavir absorption","volume":"41","author":"Dufek","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2020.06.008_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","article-title":"In\u00a0vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmpk.2020.06.008_bib20","first-page":"1599","article-title":"Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs","volume":"29","author":"Obach","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2020.06.008_bib21","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0022-3565(24)37724-9","article-title":"A\u00a0study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes","volume":"286","author":"Kawashiro","year":"1998","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"2","key":"10.1016\/j.dmpk.2020.06.008_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0026-895X(25)09935-3","article-title":"Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4","volume":"45","author":"Relling","year":"1994","journal-title":"Mol Pharmacol"},{"issue":"2\u20133","key":"10.1016\/j.dmpk.2020.06.008_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.toxicon.2009.08.007","article-title":"The algal hepatoxoxin okadaic acid is a substrate for human cytochromes CYP3A4 and CYP3A5","volume":"55","author":"Guo","year":"2010","journal-title":"Toxicon"},{"issue":"6","key":"10.1016\/j.dmpk.2020.06.008_bib24","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/dmd.32.6.666","article-title":"Gut I Different in\u00a0vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs","volume":"32","author":"Vaclavikova","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2020.06.008_bib25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-3565(25)12102-2","article-title":"Variability in human cytochrome P450 paclitaxel metabolism","volume":"275","author":"Sonnichsen","year":"1995","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"4","key":"10.1016\/j.dmpk.2020.06.008_bib26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/dmd.30.4.438","article-title":"Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship","volume":"30","author":"Cresteil","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2020.06.008_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.toxlet.2009.11.014","article-title":"Aromatic hydroxylation and catechol formation: a novel metabolic pathway of the growth promotor zeranol","volume":"192","author":"Hildebrand","year":"2010","journal-title":"Toxicol Lett"},{"issue":"1","key":"10.1016\/j.dmpk.2020.06.008_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/187231212800229336","article-title":"Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK\/JAK2\/FLT3 inhibitor","volume":"6","author":"Pasha","year":"2012","journal-title":"Drug Metabol Lett"},{"issue":"51","key":"10.1016\/j.dmpk.2020.06.008_bib29","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/bi00503a018","article-title":"Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces Cerevisiae","volume":"29","author":"Brian","year":"1990","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.dmpk.2020.06.008_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1124\/dmd.30.8.883","article-title":"Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7","volume":"30","author":"Williams","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2020.06.008_bib31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0090-9556(25)08103-6","article-title":"Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats","volume":"21","author":"Ohmori","year":"1993","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmpk.2020.06.008_bib32","first-page":"623","article-title":"Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily","volume":"25","author":"Rodrigues","year":"1997","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmpk.2020.06.008_bib33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2125.2000.00261.x","article-title":"Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin","volume":"50","author":"Westphal","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"15","key":"10.1016\/j.dmpk.2020.06.008_bib34","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/0006-2952(83)90178-8","article-title":"Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Induction and formation of metabolite-complexes: a structure-activity relationship","volume":"32","author":"Delaforge","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmpk.2020.06.008_bib35","first-page":"61","article-title":"Macrolide antibiotics as inducers and inhibitors of cytochrome P-450 in experimental animals and man","volume":"vol. 11","author":"Babany","year":"1988"},{"issue":"2","key":"10.1016\/j.dmpk.2020.06.008_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1128\/AAC.37.2.265","article-title":"Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers","volume":"37","author":"Lindstrom","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl C","key":"10.1016\/j.dmpk.2020.06.008_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/jac\/31.suppl_C.65","article-title":"Pharmacokinetics of dirithromycin","volume":"31","author":"Sides","year":"1993","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.dmpk.2020.06.008_bib38","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/clpt.1988.87","article-title":"UA Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs","volume":"43","author":"Kronbach","year":"1988","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmpk.2020.06.008_bib39","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.bcp.2004.07.012","article-title":"In\u00a0vitro metabolism of cyclosporine A by human kidney CYP3A5","volume":"68","author":"Dai","year":"2004","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.dmpk.2020.06.008_bib40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2133\/dmpk.22.328","article-title":"Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics","volume":"22","author":"Iwasaki","year":"2007","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmpk.2020.06.008_bib41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/004982598239597","article-title":"Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes","volume":"28","author":"Zeng","year":"1998","journal-title":"Xenobiotica"},{"issue":"13","key":"10.1016\/j.dmpk.2020.06.008_bib42","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/0006-2952(89)90058-0","article-title":"In\u00a0vitro interaction of rat liver cytochromes P-450 with erythromycin, oleandomycin and erythralosamine derivatives. Importance of structural factors","volume":"38","author":"Sartori","year":"1989","journal-title":"Biochem Pharmacol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436720303815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436720303815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:55:47Z","timestamp":1761162947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436720303815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1347436720303815"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2020.06.008","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applications of a grid-based CYP3A4 Template system to understand the interacting mechanisms of large-size ligands; part 4 of CYP3A4 Template study","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2020.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}